CD112R / PVRIG

Reactivity

Anti-PVRIG/CD112R clone R12 has been developed for detection of CD112R in routine formalin-fixed paraffin-embedded tissue specimen (IHC FFPE) to be used in bright field immunohistochemistry and moreover for multicolor immunofluorescence (fluorescence multiplex IHC). Anti-PVRIG/CD112R clone R12 has been validated for sensitivity and specificity on large quantities of normal and tumor tissues. Clone R12 displays no background in non lymphoid cells and in epithelial cells. Based on the high specificity combined with an inherent high signal to noise ratio clone R12 is ideally suited for multiplexed immunohistochemistry studies of CD112R in human tissue specimen.

CD112R, a member of poliovirus receptor–like proteins, is preferentially expressed on T-cells and inhibits T-cell receptor mediated signals. Blockade of the CD112R-CD112 interaction enhances T cell response. CD112R binds to its ligand CD112 which is widely expressed on antigen-presenting cells and on tumor cells. CD112R competes with CD226 to bind to CD112 and thereby acts as a coinhibitory receptor for T cells. Blockage of the CD112R–CD112 interaction enhances human T cell response.

TIGIT and CD226 constitute a T cell cosignaling pathway in which CD226 and TIGIT, respectively, serve as costimulatory and coinhibitory receptors for the ligands CD155 and CD112. This TIGIT signaling axis includes a complex receptor ligand system with the marker CD112R, which has become a promising target in cancer immuno-therapy.